AcelRx stock: buy or sell?
May 21st, 2019
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.
Should I buy AcelRx stock?Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. Having a trading plan helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
Currently, AcelRx Pharmaceuticals stock doesn't match any of these trading strategies, so our recommendation is not to buy.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is AcelRx Pharmaceuticals stock a buy?
Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 2 ratings published for ACRX stock in the last 30 days.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-5-9||LADENBURG THALM/SH SH||n/a||Buy|
|2019-2-15||Credit Suisse Group||n/a||Outperform|
AcelRx stock analysis
AcelRx shares skyrocketed 3.50% to $2.96 today.
Shares of AcelRx Pharmaceuticals skyrocketed a cool 3.50% and closed at $2.96. In the last 8 days when ACRX stock price broke down the SMA200d line, it slid $-0.35 per share (-10.57%). ACRX marked a lower low and a lower high in the short term, defining a downward trend. Climbing above $3.37 would break this short term down trend and open possibilities for reversing this situation.
After sliding a bloodcurdling -14.14% in a week last week, AcelRx closed this week at $2.96 and stepped up a fine 2.07%. Late April ACRX skyrocketed an amazing 13.99% in just one week.
Weekly chart tells us that price is in a simple uptrend, tested $2.76 level and now climbing back aiming its last top at $4.09. Since last week, when ACRX stock price broke down the 40-weeks moving avarage line, it slid $-0.35 per share (-10.57%). Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support.
AcelRx stock price history
AcelRx IPO was on February 11th, 2011 at $5.00 per share1. Since then, ACRX stock declined a -40.80%, with a yearly average of -5.10%.
1: Adjusted price after possible price splits or reverse-splits.
AcelRx stock historical price chart
ACRX stock reached 52-week highs on November at $5.05, and all-time highs 2014-03-06 with a price of 13.64.
AcelRx stock price target is $10.00Predicting the price evolution of a stock or any financial instrument in a reliable and repeatable way is probably impossible. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. The accuracy of these stock price predictions is not very high, and you should not blindly believe and make decisions only based on what this ratings or price target predictions say. Currently, only 1 price forecast for AcelRx Pharmaceuticals stock was published in the last month:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-5-9||LADENBURG THALM/SH SH||Reiterates||n/a||$10.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn March, AcelRx Pharmaceuticals missed the expectations of the analysts and posted an awful EPS of $-0.18 per share when experts were expecting $-0.20.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual revenues report draw a frightening slide of -73.10% to $2.15 M dollars. Similarly, its earnings margin (compared to sales) plummed to -2,191.96%, that is $-47.15 million.
|2013||$30 M||-||$-23.43 M-79.4%||-|
|2014||$5.22 M||-82.32%||$-33.35 M-639.3%||42.35%|
|2015||$19 M||269.24%||$-24.40 M-126.7%||-26.85%|
|2016||$17 M||-9.89%||$-43.16 M-248.6%||76.88%|
|2017||$8.00 M||-53.94%||$-51.51 M-644.3%||19.35%|
|2018||$2.15 M||-73.10%||$-47.15 M-2192.0%||-8.46%|
Quarterly financial resultsAcelRx Pharmaceuticals posted $0.61 M in revenues for 2018-Q4, a 62.60% improvement compared to previous quarter. Reported quarter earnings marked $-12.56 M with a profit margin of -2,048.61%. Profit margin rocketed a 1,255.90% compared to previous quarter when profit margin was -3,304.51%. When comparing revenues to same quarter last year, AcelRx sales marked a bloodcurdling correction and plummed a -17.16%.
|2017-Q1||$3.11 M||-||$-15.55 M-500.0%||-|
|2017-Q2||$2.66 M||-14.47%||$-13.06 M-491.0%||-16.01%|
|2017-Q3||$1.49 M||-44.10%||$-13.01 M-875.1%||-0.36%|
|2017-Q4||$0.74 M||-50.24%||$-9.89 M-1335.8%||-24.04%|
|2018-Q1||$0.34 M||-53.65%||$-11.59 M-3379.6%||17.27%|
|2018-Q2||$0.82 M||138.48%||$-10.54 M-1288.6%||-9.07%|
|2018-Q3||$0.38 M||-53.91%||$-12.46 M-3304.5%||18.19%|
|2018-Q4||$0.61 M||62.60%||$-12.56 M-2048.6%||0.80%|
AcelRx ownershipWhen you are planning to invest in shares of a stock, it's always worth to have a look its ownership structure.
AcelRx shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 11.62% of all shares.
In case of AcelRx stock, 19.73% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for ACRX stock account 0.00%, no big difference from last month.
For a better context understanding, the following table shows ownership data compared to other related stocks:
|Market cap||$233.6 M||$401.2 M||$755.3 M||$118.5 M||$67.7 M|
|Total shares||78.9 M||87.4 M||39.8 M||162.4 M||74.4 M|
|Float shares||77.7 M||59.9 M||35.1 M||155.9 M||27.1 M|
|- Institutional holdings (%)||19.7%||58.8%||62.4%||46.1%||24.4%|
|- Insider holdings (%)||11.6%||6.0%||2.9%||4.0%||63.7%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Tuesday, May 21st, 2019|
|Day range||$2.86 - $3.01|
|Average true range||$0.21|
|50d mov avg||$3.36|
|100d mov avg||$3.08|
|200d mov avg||$3.22|
AcelRx performanceTo measure stock performance is always good to benchmark with competitors or related stocks. We picked BioDelivery Sciences International, Cara Therapeutics, DURECT, Insys Therapeutics, The Medicines and Recro Pharma as the bechmarking frame for AcelRx Pharmaceuticals stock.